Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-19T05:36:59.376Z Has data issue: false hasContentIssue false
  • English
  • Français

Effects of Low-Dose Risperidone and Low-Dose Zuclopenthixol on Cognitive Functions in First-Episode Drug-Naïve Schizophrenic Patients

Published online by Cambridge University Press:  07 November 2014

Birgitte Fagerlund ,
Torben Mackeprang ,
Anders Gade ,
Ralf Hemmingsen  and
Birte Y. Glenthøj
Get access Rights & Permissions [Opens in a new window]

Abstract

Background: Studies on the effects of antipsychotics on cognitive deficits in schizophrenia mostly suggest a superior effect of atypical over typical compounds, although findings are inconsistent and effect sizes small. Several methodological issues, such as heterogenous patient samples, incomparable drug doses, effects of prior medication, construct validity, and retest effects on neuropsychological tasks, confound most results and the comparability between studies. Consequently, the conclusion concerning effects of antipsychotics on cognition is still equivocal.

Objective: The present randomized clinical trial examined the effects on cognition of comparatively low doses of a typical antipsychotic (zuclopenthixol) and an atypical antipsychotic (risperidone) in a homogenous group of drug-naïve first-episode schizophrenic patients in a longitudinal setting.

Methods: First-episode schizophrenic patients who had never previously been exposed to antipsychotic treatment (N-25) were randomly allocated to treatment with flexible doses of zuclopenthixol or risperidone in an open-label design. Cognitive functions were examined both when patients were drug-naïve, and after 13 weeks of treatment. A comprehensive neuropsychological battery was used in order to optimize construct validity, and principal components of cognitive functions were extrapolated in order to reduce type I errors. A healthy control group was tested at baseline and after 13 weeks, in order to examine retest effects. The cognitive domains studied were executive functions, selective attention, and reaction time.

Results: The patients showed considerable cognitive deficits when drug-naïve. There were few differential effects of risperidone and zuclopenthixol on cognitive deficits, except for a differential significance, respectively, tendency towards improved reaction and movement times in the risperidone group, and a lack of such in the zuclopenthixol group. These differences were no longer significant after covarying for extrapyramidal side effects and anticholinergic medication that were more prevalent in the zuclopenthixol group and the increases after medication were comparable with retest effects in controls.

Conclusion: The study underscores the importance of examining impact of factors, such as clinical improvement, extrapyramidal side effects, anticholinergic medication and retest effects in longitudinal efficacy studies. This study does not support efficacy of either risperidone or zuclopenthixol on cognitive functions in drug-naïve schizophrenia patients after 3 months of medication, because neither could be distinguished from retest effects of the healthy control group.

Type
Original Research
Information
CNS Spectrums , Volume 9 , Issue 5 , May 2004 , pp. 364 - 374
Copyright
Copyright © Cambridge University Press 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Bilder, RM, Goldman, RS, Robinson, D, et al.Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry. 2000;157:549–59.CrossRefGoogle ScholarPubMed
2.Green, MF, Nuechterlein, KH. Should schizophrenia be treated as a neurocognitive disorder? Schizophr Bull. 1999;25:309–319.CrossRefGoogle ScholarPubMed
3.Green, MF, Braff, DL. Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications. Biol Psychiatry. 2001;49:374–384.CrossRefGoogle ScholarPubMed
4.Green, MF, Kern, RS, Braff, DL, Mintz, J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull. 2000;26:119–136.CrossRefGoogle ScholarPubMed
5.Velligan, DI, Mahurin, RK, Diamond, PL, Hazelton, BC, Eckert, SL, Miller, AL. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr Res. 1997;25:21–31.CrossRefGoogle ScholarPubMed
6.Velligan, DI, Miller, AL. Cognitive dysfunction in schizophrenia and its importance to outcome: the place of atypical antipsychotics in treatment. J Clin Psychiatry. 1999;60 (suppl):25–28Google ScholarPubMed
7.Bilder, RM, Goldman, RS, Volavka, J, et al.Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002:159:1018–1028.CrossRefGoogle ScholarPubMed
8.Harvey, PD, Green, MF, McGurk, SR, Meltzer, HY. Changes in cognitive functioning with risperidone and olanzapine treatment: a targe-scale, double-blind, randomized study. Psychopharmacology (Berl). 2003;169:404–411.CrossRefGoogle ScholarPubMed
9.Lysaker, P, Bell, M, Beam-Goulet, J. Wisconsin card sorting test and work performance in schizophrenia. Psychiatry Res. 1995;56:45–51.CrossRefGoogle ScholarPubMed
10.Bollini, P, Pampallona, S, Orza, MJ, Adams, ME, Chalmers, TC. Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials. Psychol Med. 1994;24:307–316.CrossRefGoogle ScholarPubMed
11.Geddes, J, Freemantle, N, Harrison, P, Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321:1371–1376.CrossRefGoogle ScholarPubMed
12.Leucht, S, Pitschel-Walz, G, Abraham, D, Kissling, W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999;35:51–68.CrossRefGoogle ScholarPubMed
13.Harvey, PD, Keefe, RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001;158:176–184.CrossRefGoogle ScholarPubMed
14.Keefe, RS, Silva, SG, Perkins, DO, Lieberman, JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull. 1999;25:201–222.CrossRefGoogle ScholarPubMed
15.Kern, RS, Green, MF, Marshall, BD Jr, et al.Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. Biol Psychiatry. 1998;44:726–732.CrossRefGoogle ScholarPubMed
16.Kern, RS, Green, MF, Marshall, BD Jr, et al.Risperidone versus haloperidol on secondary memory: can newer medications aid learning? Schizophr Bull. 1999;25:223–232.CrossRefGoogle ScholarPubMed
17.Meltzer, HY, McGurk, SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 1999;25:233–255.CrossRefGoogle ScholarPubMed
18.Purdon, SE. Cognitive improvement in schizophrenia with novel antipsychotic medications. Schizophr Res. 1999;35(suppl):S51–S60.CrossRefGoogle ScholarPubMed
19.Purdon, SE, Jones, BD, Stip, E, et al.Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry. 2000;57:249–258.CrossRefGoogle ScholarPubMed
20.Velligan, DI, Newcomer, J, Pultz, J, et al.Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res. 2002;53:239–248.CrossRefGoogle ScholarPubMed
21.Green, MF, Marder, SR, Glynn, SM, et al.The neurocognitive effects of lowdose haloperidol: a two-year comparison with risperidone. Biol Psychiatry. 2002;51:972–978.CrossRefGoogle ScholarPubMed
22.Carpenter, WT, Gold, JM. Another view of therapy for cognition in schizophrenia. Biol Psychiatry. 2002;51:969–71.CrossRefGoogle ScholarPubMed
23.Carpenter, WT, Gold, JM. Reply. Biol Psychiatry. 2003;53:267–268.CrossRefGoogle Scholar
24.Meltzer, HY, Sumiyoshi, T. Atypical antipsychotic drugs improve cognition in schizophrenia. Biol Psychiatry. 2003;53:265–267.CrossRefGoogle ScholarPubMed
25.Spohn, HE, Strauss, ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol. 1989;98:367–380.CrossRefGoogle ScholarPubMed
26.Sweeney, JA, Keilp, JG, Haas, GL, Hill, J, Weiden, PJ. Relationships between medication treatments and neuropsychological test performance in schizophrenia. Psychiatry Res. 1991;37:297–308.CrossRefGoogle ScholarPubMed
27.The ICD-10 Classification of Mental and Behavioral Disorders. Geneva, Switzerland: World Health Organization; 1993.Google Scholar
28.Schedules for Clinical Assessment in Neuropsychiatry. Geneva, Switzerland: World Health Organization; 1994.Google Scholar
29.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar
30.Amin, S, Singh, SP, Brewin, J, Jones, PB, Medley, I, Harrison, G. Diagnostic stability of first-episode psychosis. Comparison of ICD-10 and DSM-III-R systems. Br J Psychiatry. 1999;175:537–543.CrossRefGoogle ScholarPubMed
31.Glenthoj, BY, Gerlach, J, Licht, R, Gulmann, N, Jorgensen, OS. Guidelines for treatment with antipsychotics. [in danish]. Journal of the Danish Medical Association. 1998; Klaringsrapport nr. 5.Google Scholar
32.Mackeprang, T, Kristiansen, KT, Glenthoj, BY. Effects of antipsychotici on prepulse inhibition of the startle response in drug-naive schizophrenic patients. Biol Psychiatry. 2002;52:863–873.CrossRefGoogle ScholarPubMed
33.Lowe, C, Rabbitt, P. Test/re-test reliability of the CANTAB and ISPOCD neuropsychological batteries: theoretical and practical issues. Cambridge Neuropsychological Test Automated Battery. International Study of Post-Operative Cognitive Dysfunction. Neuropsychologia. 1998;36:915–923.CrossRefGoogle Scholar
34.Sahakian, BJ, Owen, AM. Computerized assessment in neuropsychiatry using CANTAB: discussion paper. J R Soc Med. 1992;85:399–402.Google ScholarPubMed
35.Milner, B. Effects of different brain lesions on card sorting. Arch Neurol. 1963;9:90–100.CrossRefGoogle Scholar
36.Reitan, RM, Wolfson, D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tucson, Ariz: Neuropsychology Press; 1993.Google Scholar
37.Nelson, HE, O'Connell, A. Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test. Cortex. 1978;14:234–244.CrossRefGoogle ScholarPubMed
38.Heaton, RK, Gladsjo, JA, Palmer, BW, Kuck, J, Marcotte, TD, Jeste, DV. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry. 2001;58:24–32.CrossRefGoogle ScholarPubMed
39.Regard, M, Strauss, E, Knapp, P. Children's production on verbal and non-verbal fluency tasks. Percept Mot Skills. 1982;55:839–844.CrossRefGoogle ScholarPubMed
40.Goldstein, G, Watson, JR. Test-retest reliability of the Halstead-Reitan battery and the WAIS in a neuropsychiatric population. Clinical Neuropsychologist. 1989;3:265–272.CrossRefGoogle Scholar
41.Boone, DE. Reliability of the WAIS-R with psychiatric inpatients. J Clin Psychol. 1992;48:72–76.3.0.CO;2-0>CrossRefGoogle ScholarPubMed
42.Weber, B. RBANS has reasonable test-retest reliability in schizophrenia. Evid Based Ment Health. 2003;6:22.CrossRefGoogle ScholarPubMed
43.Danion, JM, Meulemans, T, Kauffmann-Muller, F, Vermaat, H. Intact implicit learning in schizophrenia. Am J Psychiatry. 2001;158:944–948.CrossRefGoogle ScholarPubMed
44.Meltzer, HY, Park, S, Kessler, R. Cognition, schizophrenia, and the atypical antipsychotic drugs. Proc Natl Acad Sci U S A. 1999;96:13591–13593.CrossRefGoogle ScholarPubMed
45.Duncan, EJ, Szilagyi, S, Efferen, TR, et al.Effect of treatment status on prepulse inhibition of acoustic startle in schizophrenia. Psychopharmacology (Berl). 2003;167:63–71.CrossRefGoogle ScholarPubMed
46.Hong, KS, Kim, JG, Koh, HJ, et al.Effects of risperidone on information processing and attention in first-episode schizophrenia. Schizophr Res. 2002;53:7–16.CrossRefGoogle ScholarPubMed